These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38346360)

  • 1. QuantiFERON-CMV assay by chemiluminescence immunoassay: Is it more suitable for real-live monitoring of transplant patients?
    Fernández-Moreno R; Páez-Vega A; Rodríguez-Cano D; Salinas A; Rodríguez-Cantalejo F; Jurado A; Torre-Cisneros J; Cantisán S
    J Clin Virol; 2024 Apr; 171():105651. PubMed ID: 38346360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the fully automated LIAISON®XL chemiluminescence analyzer for QuantiFERON®-CMV testing in transplant recipients.
    Mafi S; Alain S; Hantz S
    J Clin Virol; 2023 Sep; 166():105550. PubMed ID: 37527584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. QuantiFERON-TB Gold Plus with Chemiluminescence Immunoassay: Do We Need a Higher Cutoff?
    Bisognin F; Lombardi G; Re MC; Dal Monte P
    J Clin Microbiol; 2020 Sep; 58(10):. PubMed ID: 32759352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of concordance of new QuantiFERON-TB Gold Plus platforms for
    Ruiz-Tagle C; García P; Hernández M; Balcells ME
    Microbiol Spectr; 2024 Aug; 12(8):e0046924. PubMed ID: 38975791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Fully Automated Chemiluminescence Analyzer Liaison XL for the Performance of the QuantiFERON-TB Gold Plus Assay in an Area with a Low Incidence of Tuberculosis.
    Fernández-Huerta M; Moreto C; Vila-Olmo N; García de Cara EI; Basaez MC; Santín M; Alcaide F
    J Clin Microbiol; 2021 Jul; 59(8):e0060321. PubMed ID: 34076474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflated Gamma Interferon Response with QuantiFERON-TB Gold Plus Using the Automated Liaison XL Analyzer: a Testing Algorithm To Mitigate False-Positive Results in Low-Incidence Settings.
    Buron V; Banaei N
    J Clin Microbiol; 2023 Jun; 61(6):e0029523. PubMed ID: 37195172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Utility of QuantiFERON-Cytomegalovirus Test in Management of Kidney Transplant Recipients.
    Tarasewicz A; Dębska-Ślizień A; Rutkowski B
    Transplant Proc; 2016 Jun; 48(5):1650-3. PubMed ID: 27496465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients.
    Abate D; Saldan A; Mengoli C; Fiscon M; Silvestre C; Fallico L; Peracchi M; Furian L; Cusinato R; Bonfante L; Rossi B; Marchini F; Sgarabotto D; Rigotti P; Palù G
    J Clin Microbiol; 2013 Aug; 51(8):2501-7. PubMed ID: 23678073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of an Advanced Interferon-Gamma Release Assay for Mycobacterium tuberculosis Detection.
    Altawallbeh G; Gabrielson D; Peters JM; Killeen AA
    J Appl Lab Med; 2021 Sep; 6(5):1287-1292. PubMed ID: 33829248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytomegalovirus Infection Monitoring Based on Interferon Gamma Release Assay in Kidney Transplantation.
    De Gracia-Guindo MDC; Ruiz-Fuentes MDC; Galindo-Sacristán P; Osorio-Moratalla JM; Ruiz-Fuentes N; Rodriguez Granger J; Osuna-Ortega A
    Transplant Proc; 2018 Mar; 50(2):578-580. PubMed ID: 29579857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients.
    Gliga S; Korth J; Krawczyk A; Wilde B; Horn PA; Witzke O; Lindemann M; Fiedler M
    J Clin Virol; 2018 Aug; 105():91-96. PubMed ID: 29936407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance Evaluation of a New Automated Chemiluminescent Immunoanalyzer-Based Interferon-Gamma Releasing Assay AdvanSure I3 in Comparison With the QuantiFERON-TB Gold In-Tube Assay.
    Kim JJ; Park Y; Choi D; Kim HS
    Ann Lab Med; 2020 Jan; 40(1):33-39. PubMed ID: 31432637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D; Perkowska-Ptasinska A; Sadowska A; Gozdowska J; Ciszek M; Serwanska-Swietek M; Domagala P; Miszewska-Szyszkowska D; Sitarek E; Jozwik A; Kwiatkowski A; Durlik M
    BMC Infect Dis; 2018 Apr; 18(1):179. PubMed ID: 29661141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients.
    Lee H; Park KH; Ryu JH; Choi AR; Yu JH; Lim J; Han K; Kim SI; Yang CW; Chung BH; Oh EJ
    PLoS One; 2017; 12(12):e0189488. PubMed ID: 29232714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of evidence of association between IFNG and IL28B polymorphisms and QuantiFERON-CMV test results in seropositive transplant patients.
    Aguado R; Páez-Vega A; Agüera ML; Montejo M; Guirado L; Fortún J; Suárez-Benjumea A; Len O; Fariñas MC; de Gracia C; Hernández D; Cobos-Ceballos MJ; Torre-Cisneros J; Cantisán S; ;
    Hum Immunol; 2018 Jun; 79(6):499-505. PubMed ID: 29605690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Usefulness of Monitoring Cytomegalovirus-Specific Immunity by Quantiferon-CMV in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients.
    Lee SM; Kim YJ; Yoo KH; Sung KW; Koo HH; Kang ES
    Ann Lab Med; 2017 May; 37(3):277-281. PubMed ID: 28224776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of CMV-specific cell-mediated immunity with a commercial ELISA-based interferon-γ release assay in kidney transplant recipients treated with antithymocyte globulin.
    Fernández-Ruiz M; Rodríguez-Goncer I; Parra P; Ruiz-Merlo T; Corbella L; López-Medrano F; Polanco N; González E; San Juan R; Folgueira MD; Andrés A; Aguado JM
    Am J Transplant; 2020 Aug; 20(8):2070-2080. PubMed ID: 31991045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative evaluation of CLIA and EIA for Quantiferon-TB Gold Plus.
    Brantestig S; Kinnunen A; Almeflo S; Restorp K; Ahlqvist J; Dyrdak R
    APMIS; 2020 Apr; 128(4):343-349. PubMed ID: 31976577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of cytomegalovirus (CMV)-specific cell-mediated immune response using QuantiFERON-CMV assay in CMV-seropositive healthy volunteers: fact not artifact.
    Valle-Arroyo J; Aguado R; Páez-Vega A; Pérez AB; González R; Fornés G; Torre-Cisneros J; Cantisán S
    Sci Rep; 2020 Apr; 10(1):7194. PubMed ID: 32346028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QuantiFERON-CMV and monitor predict cytomegalovirus, mortality, and graft-versus-host disease in transplant recipients.
    Souan L; Jazar HA; Nashwan S; Sughayer MA
    J Med Virol; 2023 Nov; 95(11):e29250. PubMed ID: 38009250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.